Bristol biotech spinout Dimension raises £700,000 to detect hidden vascular disease
What's the deal? Dimension BiotechnologiesDealroom has a profile for this one. Try Dealroom →, a University of BristolDealroom has a profile for this one. Try Dealroom → spinout, has raised more than £700,000 in pre-seed funding to develop a blood test for microvascular disease. The company is building a test that reveals biochemical signs of damage in the body's smallest blood vessels.
Who's backing it? The round combines £490,000 from Kidney Research UKDealroom has a profile for this one. Try Dealroom →, the University of Bristol, local angel investors, and the KQ Labs AcceleratorDealroom has a profile for this one. Try Dealroom → at the Francis Crick InstituteDealroom has a profile for this one. Try Dealroom →. A further £215,000 comes from Innovate UKDealroom has a profile for this one. Try Dealroom → grant funding, including its Investor Partnerships programme.
What's the endgame? Damage to the microvasculature underlies major conditions including kidney disease, cardiovascular disease, and dementia, but it remains hard to detect in clinical practice. Dimension's platform measures changes in the glycocalyx — a sugar-rich layer that coats the inside of blood vessels — using signatures carried on circulating red blood cells.
The approach generates a biochemical "fingerprint" of microvascular health from a single blood sample, without imaging equipment or tissue biopsies.
Why now? The company was founded on decades of research by Professor Simon Satchell and Dr Matthew Butler of Bristol's Bristol Renal group, both consultant nephrologists at North Bristol NHS TrustDealroom has a profile for this one. Try Dealroom →. Their recent breakthroughs in glycocalyx biology were published in Nature Communications earlier this year.
Who's running it? The scientific founders have been joined by chief executive officer Dr Arne Scott and chief operating officer Dr Ulrike Gorochowski, both formerly of Bristol spinout Rosa BiotechDealroom has a profile for this one. Try Dealroom →, plus Professor Steve Harper, co-founder of ExonateDealroom has a profile for this one. Try Dealroom → and IsomAb.
"Doctors can see the consequences of microvascular disease every day, but they lack practical tools to measure it directly," Scott said. The goal, he added, is to make microvascular health "measurable through a routine blood test."
The signal: University spinouts backed by disease charities and public grants remain a key route for turning long-run academic research into clinical tools. Dimension's bet is that a simple blood test can bring microvascular monitoring — long confined to labs — into mainstream medicine.
Read more: bristol.ac.uk
Image credit: Generated with Gemini
